Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ånström M, Bodin L, Nilsson I and Tidefelt U (2000) Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden. Br J Cancer 82: 1387–1392
Ferrara F and Mirto S (1996) Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly. Br J Haematol 92: 627–631
Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B and Buchner T (1999) Management of acute myeloid leukaemia in elderly patients. J Clin Oncol 17: 3569–3576
Shamash J, Oliver R, Gallagher C, Newland A, Lister T, Kelsey S, Gupta R and O'Doherty C (2000) Pre-induction LDH as a prognostic factor for outcome of high dose chemotherapy (HDCT) for germ cell tumours relapsing or refractory to conventional chemotherapy. Br J Cancer 82: 2022–2023
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Dalley, C., Lister, T., Cavenagh, J. et al. Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia. Br J Cancer 84, 147 (2001). https://doi.org/10.1054/bjoc.2000.1537
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1537
This article is cited by
-
The expression of melanoma-associated antigen A (MAGE-A) in oral squamous cell carcinoma: an evaluation of the significance for tumor prognosis
Oral and Maxillofacial Surgery (2019)